Do lipid lowering drugs reduce the risk of coronary heart disease?
| Autor: | Pritzker Lb |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Clinical Biochemistry Probucol Coronary Disease Coronary Artery Disease General Biochemistry Genetics and Molecular Biology Coronary artery disease chemistry.chemical_compound Internal medicine Hyperlipidemia medicine Humans Myocardial infarction Clofibrate Hypolipidemic Agents Pravastatin Clinical Trials as Topic Cholestyramine Cholesterol business.industry Anticholesteremic Agents Biochemistry (medical) Angiography medicine.disease Clinical trial Europe Lipoproteins LDL Survival Rate chemistry Cardiology business Niacin medicine.drug |
| Zdroj: | Critical reviews in clinical laboratory sciences. 35(6) |
| ISSN: | 1040-8363 |
| Popis: | Historically, a wide range of drugs have been used to treat hyperlipidemias. These include fibrates whose main action is to lower plasma triglycerides; bile-acid sequestering resins introduced to reduce plasma cholesterol; and more recently a family of statins designed to inhibit the rate-limiting enzyme of cholesterol biosynthesis, HMG-CoA reductase. Early trials employing rather small numbers of subjects with established coronary artery disease (CAD) demonstrated that lipid reduction was often but not always associated with a lowered incidence of clinical end-points, including death and non-fatal myocardial infarction. However, significant angiographic benefit was rarely demonstrated in these investigations. More recent trials based on statins have shown a reduction in clinical events not only in patients with CAD, but also in healthy subjects given these drugs for primary prevention. Differences in design, duration, the role of confounders such as risk factors other than lipids, and the frequently poor correlation between angiographic changes and clinical outcomes are discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|